Safe Concurrent Use of Anti-tuberculosis Drugs and Pembrolizumab in a Patient with Non-small-cell Lung Cancer Who Was Infected with Mycobacterium tuberculosis |
| |
| Authors: | Kenji Nakahama Hiroyasu Kaneda Koichi Ogawa Yoshiya Matsumoto Yoko Tani Tomohiro Suzumura Shigeki Mitsuoka Tetsuya Watanabe Kazuhisa Asai Tomoya Kawaguchi |
| |
| Affiliation: | 1.Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Japan; 2.Department of Clinical Oncology, Graduate School of Medicine, Osaka City University, Japan |
| |
| Abstract: | A 68-year-old Japanese man was diagnosed with lung adenocarcinoma stage IVB. We introduced a first-line chemotherapy of four cycles of carboplatin and pemetrexed and pembrolizumab, followed by pemetrexed and pembrolizumab maintenance therapy. Approximately four months after anticancer therapy, a small nodule appeared in the right peripheral S3 lesion. After five months, the nodule was confirmed as a Mycobacterium tuberculosis (TB) nodule. We initiated anti-TB therapy without stopping pembrolizumab, and the right S3 nodule shrank immediately. This report supports the concurrent use of anti-TB treatment with an immune checkpoint inhibitor when the TB infection area is limited. |
| |
| Keywords: | pembrolizumab lung cancer tuberculosis adverse event immune checkpoint inhibitor |
|
|
